8-K: Relay Therapeutics Strengthens Board with Appointment of Oncology and Business Development Expert Claire Mazumdar

Relay Therapeutics, a clinical-stage precision medicine company, announced the appointment of Claire Mazumdar, Ph.D., MBA, to its Board of Directors and as Chair of the Audit Committee, following the resignation of Jami Ruben.

Summary

• Jami Ruben resigned as a Class III Director and member of the Audit Committee of Relay Therapeutics, Inc. on June 8, 2025, with her resignation not being the result of any dispute or disagreement with the Company.
• Claire Mazumdar, Ph.D., MBA, was appointed as a Class III Director and Chair of the Audit Committee, effective June 9, 2025, following a recommendation from the Nominating and Corporate Governance Committee.
• Dr. Mazumdar has been determined to be independent under Nasdaq listing standards and the Company's corporate governance guidelines, and her term as a Class III director will expire at the annual meeting of stockholders in 2026.
• As a non-employee director, Dr. Mazumdar will receive cash compensation and equity awards, including an initial option to purchase 421,241 shares of common stock at an exercise price of $3.36 per share, vesting monthly over 36 months.
• Dr. Mazumdar brings extensive experience as the founding CEO of Bicara Therapeutics and prior roles in business development and corporate strategy at Rheos Medicines and Third Rock Ventures, with a focus on clinical-stage oncology.
• Relay Therapeutics issued a press release on June 11, 2025, announcing Dr. Mazumdar's appointment, emphasizing her strategic and operational experience in clinical-stage oncology as the company prepares to initiate its Phase 3 ReDiscover-2 trial in breast cancer.

Sentiment

Score: 7

Explanation: The appointment of a highly qualified and independent director with relevant industry experience, particularly in clinical-stage oncology and business development, is a positive step for corporate governance and strategic guidance, especially as the company prepares for a Phase 3 trial. The resignation was not due to any dispute.

Positives

• The appointment of Claire Mazumdar, Ph.D., MBA, an independent director with significant strategic and operational experience in clinical-stage oncology, strengthens the Board's expertise.
• Dr. Mazumdar's background as founding CEO of Bicara Therapeutics and her roles in business development at Rheos Medicines and Third Rock Ventures align well with Relay Therapeutics' strategic goals.
• Her appointment as Chair of the Audit Committee enhances corporate governance and financial oversight.
• The company is preparing to initiate its Phase 3 ReDiscover-2 trial in breast cancer soon, indicating progress in its clinical pipeline.

Risks

• Restructuring activities may be more costly or time-consuming than expected or may not achieve their intended results.
• The timing, execution, and expected impact of restructuring plans, including workforce reductions, may differ from expectations.
• The expected decrease in annual spending and sufficiency of existing cash resources may not materialize as anticipated.
• Internal and external costs for ongoing and planned activities may be higher than expected, leading to faster cash burn or changes/curtailment of plans.
• Global economic uncertainty, geopolitical instability, conflicts, or public health epidemics could impact operations, clinical trial timing/results, strategy, future operations, and profitability.
• Significant political, trade, or regulatory developments, such as tariffs, are beyond the company's control and could have adverse effects.
• Clinical trials or drug candidate development may experience delays or pauses.
• Preliminary or interim results of preclinical or clinical trials may not be predictive of future or final results, and interim data may change as more patient data become available.
• The company's ability to successfully demonstrate the safety and efficacy of its drug candidates is not guaranteed.
• The timing and outcome of planned interactions with regulatory authorities are uncertain.
• Obtaining, maintaining, and protecting intellectual property is subject to risks.

Future Outlook

Relay Therapeutics is preparing to initiate its Phase 3 ReDiscover-2 trial in breast cancer soon. The company's strategy, business plans, and focus include advancing its clinical development programs, realizing therapeutic benefits and potential efficacy of its drug candidates, managing regulatory interactions, assessing market opportunities, and optimizing cash runway and capital use, while implementing cost-saving measures.

Management Comments

• "It is a privilege to welcome Claire to our Board, where she will draw from her strategic and operational experience in clinical-stage oncology to offer guidance as we prepare to initiate our Phase 3 ReDiscover-2 trial in breast cancer soon," said Sanjiv Patel, M.D., President and Chief Executive Officer of Relay Therapeutics.

Industry Context

Relay Therapeutics operates in the highly competitive clinical-stage precision medicine sector, leveraging advanced computational and experimental technologies for drug discovery, particularly in targeted oncology and genetic diseases. The appointment of Dr. Mazumdar, with her background in clinical-stage oncology and business development from companies like Bicara Therapeutics and Rheos Medicines, reflects the industry's emphasis on strong scientific and strategic leadership as companies advance their pipelines towards late-stage clinical trials.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Potentially positive impact due to enhanced corporate governance and strategic oversight provided by an experienced, independent director, which could instill greater confidence in the company's leadership and future direction.
• Patients/Customers: Indirect positive impact if strengthened governance and strategic guidance lead to more efficient and successful development of life-changing therapies, particularly with the upcoming Phase 3 trial in breast cancer.

Next Steps

• Initiate the Phase 3 ReDiscover-2 trial in breast cancer.
• Dr. Mazumdar will serve as a Class III director until the annual meeting of stockholders in 2026.

Key Dates

Recommendation

Keywords

Relay Therapeutics, RLAY, Board of Directors, Claire Mazumdar, Jami Ruben, corporate governance, biotechnology, precision medicine, oncology, drug discovery, clinical-stage, Audit Committee, SEC filing, 8-K